Evidence map›Paper›PMID 33637604›Full record

ArticleCancer immunology research2021

Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model.

Casey R Ager, Aleksandar Z Obradovic, Juan M Arriaga, Matthew G Chaimowitz, Andrea Califano, Cory Abate-Shen, Charles G Drake

Open access · bronzeAbstract read
In one paragraph

Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Multi-stage mechanisms of tumor metastasis and therapeutic strategies.Signal transduction and targeted therapy · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Casey R AgerColumbia Center for Translational Immunology (CCTI), Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-0507-700X
Aleksandar Z ObradovicColumbia Center for Translational Immunology (CCTI), Columbia University Irving Medical Center, New York, New York.
Juan M ArriagaDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York.
Matthew G ChaimowitzColumbia Center for Translational Immunology (CCTI), Columbia University Irving Medical Center, New York, New York.
Andrea CalifanoDepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-4742-3679
Cory Abate-ShenDepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York.
Charles G DrakeColumbia Center for Translational Immunology (CCTI), Columbia University Irving Medical Center, New York, New York. cgd2139@columbia.edu.
Columbia University Irving Medical Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5M
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1M
Preclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1M
Molecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1M
High-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0M
Storage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600k
Discovering Network-Based Drivers of Single-Cell Transcriptional State in Tumor Immune Microenvironment to Reveal Immuno-Therapeutic Targets and Treatment SynergiesF30CA260765 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI OBRADOVIC, ALEKSANDAR ZORAN · 2021 to 2022
$98k
NCATS NIH HHS UL1 TR001873NCI NIH HHS F30 CA260765NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R35 CA197745NCI NIH HHS U01 CA217858NIH HHS S10 OD012351NIH HHS S10 OD021764
6 · The paper itself

Abstract

The theory of cancer immunoediting, which describes the dynamic interactions between tumors and host immune cells that shape the character of each compartment, is foundational for understanding cancer immunotherapy. Few models exist that facilitate in-depth study of each of the three canonical phases of immunoediting: elimination, equilibrium, and escape. Here, we utilized NPK-C1, a transplantable prostate tumor model that we found recapitulated the three phases of immunoediting spontaneously in immunocompetent animals. Given that a significant portion of NPK-C1 tumors reliably progressed to the escape phase, we were able to delineate cell types and mechanisms differentially prevalent in equilibrium versus escape phases. Using high-dimensional flow cytometry, we found that activated CD4

Indexed as

Tumor EscapeAnimalsAntigens, CDCD8-Positive T-LymphocytesDisease Models, AnimalFlow CytometryIntegrin alpha ChainsMaleMiceMice, Inbred C57BLPhenotypeProstatic NeoplasmsT-Lymphocytes, CytotoxicT-Lymphocytes, RegulatoryTumor BurdenTumor Microenvironmentalpha E integrinsAntigens, CDIntegrin alpha Chains

Identifiers

PMID33637604
PMCPMC8102339
OpenAlexW3131054640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.